Speedway Scene reporting, analysis and commentary on Casgevy, pulled together from across our coverage.
Federal regulators lowered the age floor for Vertex's one-time gene-editing therapy from 12 to 2, making Casgevy the first genetic medicine indicated for young children with two inherited blood disorders.
Everything Speedway Scene has published on Casgevy, gathered in one place: the reporting, the analysis and the commentary that track the subject.
The developments in markets, business and world affairs that will set the day, distilled into one authoritative email.
